Fuan Pharmaceutical's subsidiary, Nitrazine raw material medicine, receives FDA registration approval notice.

Fuan Pharmaceutical (300194.SZ) announced that its wholly-owned subsidiary, Guang'an Kait Pharmaceutical Co., Ltd. (referred to as "Guang'an Kait"), has recently received a registration approval notification for the raw material drug Diazoxide issued by the U.S. Food and Drug Administration (FDA). Diazoxide is a fast-acting antihypertensive drug and insulin secretion inhibitor, mainly used for the treatment of hypertensive crises and hypoglycemia related to insulinomas. It works by activating potassium ion channels in vascular smooth muscle, dilating blood vessels to reduce blood pressure, while also inhibiting the release of insulin by pancreatic -cells, regulating blood sugar levels.